Gene-based therapeutics, together with siRNA and mRNA, provide promising methods for disease-related gene modulation however stay restricted by challenges in systemic supply and intracellular launch. We report a modularly designed peptide-based provider able to delivering each siRNA and mRNA in vitro and in vivo. The provider self-assembles from three useful peptide sequences incorporating modules for lysosomal escape (RRGK and leucine repeats), tumor-associated concentrating on (RGDK and GYQTI), and enhanced structural stability (long-chain serine). In vitro, the siRNA@peptide complicated achieved 97% mobile uptake and 75% GFP gene silencing effectivity in HeLa cells. For mRNA supply, the provider promoted strong GFP expression in vitro and enabled tumor-associated luciferase expression in vivo. Moreover, systemic administration of siRNA formulated with the optimized provider resulted in measurable gene silencing in a number of organs, confirming its in vivo useful supply functionality. Collectively, these outcomes set up a modular peptide platform for systemic gene supply, demonstrating efficient in vivo gene expression and gene silencing whereas sustaining acceptable biosafety. This research gives a flexible framework for the rational improvement of peptide-based nucleic acid supply methods.
